A Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT ID: NCT00421993

Last Updated: 2021-02-18

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1670 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center, randomized, double-blind, parallel group study with 12 weeks of treatment of acne vulgaris. Efficacy and safety evaluations will be performed at Screening (safety only), Baseline and Weeks 1, 2, 4, 8 and 12. All Investigator's Global Assessment evaluators and lesion counters must be trained and approved by Galderma. The evaluator of a subject should remain the same during the study.

The primary objective is to demonstrate the superiority in efficacy and assess safety of Adapalene/Benzoyl Peroxide Topical Gel (Adapalene/Benzoyl Peroxide Gel) versus Adapalene Topical Gel, 0.1% (Adapalene Monad); Benzoyl Peroxide Topical Gel, 2.5% (Benzoyl Peroxide Monad) and Topical Gel Vehicle (Gel Vehicle) in the treatment of acne vulgaris for up to 12 weeks.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acne Vulgaris

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Adapalene/Benzoyl Peroxide Topical Gel

Group Type EXPERIMENTAL

Adapalene/Benzoyl Peroxide

Intervention Type DRUG

Topical Gel, One application daily in the evening for 12 weeks

2

Adapalene Topical Gel

Group Type ACTIVE_COMPARATOR

Adapalene

Intervention Type DRUG

Topical Gel,One application daily in the evening for 12 weeks

3

Benzoyl Peroxide Topical Gel

Group Type ACTIVE_COMPARATOR

Benzoyl Peroxide

Intervention Type DRUG

Topical Gel, one application daily in the evening for 12 weeks

4

Topical Gel Vehicle

Group Type PLACEBO_COMPARATOR

Topical Gel Vehicle

Intervention Type DRUG

Topical Gel Vehicle,one application daily in the evening for 12 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Adapalene/Benzoyl Peroxide

Topical Gel, One application daily in the evening for 12 weeks

Intervention Type DRUG

Adapalene

Topical Gel,One application daily in the evening for 12 weeks

Intervention Type DRUG

Benzoyl Peroxide

Topical Gel, one application daily in the evening for 12 weeks

Intervention Type DRUG

Topical Gel Vehicle

Topical Gel Vehicle,one application daily in the evening for 12 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* A clinical diagnosis of acne vulgaris with facial involvement.
* A minimum of 20 but not more than 50 Inflammatory lesions
* A minimum of 30 but not more than 100 Noninflammatory lesions
* A score of 3 (Moderate) on the Investigator's Global Assessment Scale.

Exclusion Criteria

* More than one acne nodule or any acne cyst.
* Acne conglobata, acne fulminans, secondary acne, or severe acne.
* Known previous participation in an Adapalene/Benzoyl Peroxide Topical Gel Trial.
* Underlying diseases that require the use of interfering topical or systemic therapy.
* Use of prohibited medications prior to the study unless appropriate washout period is documented
* Use of hormonal contraceptives solely for control of acne
Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Galderma R&D

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Galderma

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Michael Graeber, MD

Role: STUDY_DIRECTOR

Galderma R&D

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Medical Affliated Research Center

Huntsville, Alabama, United States

Site Status

Dermatology Research of Arkansas

Little Rock, Arkansas, United States

Site Status

Associates in research, Inc.

Fresno, California, United States

Site Status

University of California, Irvine

Irvine, California, United States

Site Status

Dermatology Research Associates

Los Angeles, California, United States

Site Status

Marcia J. Glenn, MD and Associates, Dermatology & Laser center, Inc

Marina del Rey, California, United States

Site Status

Affiliated Research Institute

San Diego, California, United States

Site Status

University at San Francisco Medical Center

San Francisco, California, United States

Site Status

Radiant Research

Santa Rosa, California, United States

Site Status

Dr Weintraub James

Simi Valley, California, United States

Site Status

The George Washington University Medical Center

Washington D.C., District of Columbia, United States

Site Status

Visions Clinical Research

West Palm Beach, Florida, United States

Site Status

Atlanta Dermatology and Vein Research Center

Alpharetta, Georgia, United States

Site Status

SKINQRI

Lincolnshire, Illinois, United States

Site Status

Welborn Clinic

Evansville, Indiana, United States

Site Status

Dawes Fretzin Clinical Research Group, LLC

Indianapolis, Indiana, United States

Site Status

Dolby Research, LLC

Baton Rouge, Louisiana, United States

Site Status

Hamzavi Dermatology

Port Huron, Michigan, United States

Site Status

Somerset Skin Clinic

Troy, Michigan, United States

Site Status

James Del Rosso, DO - Office of Dr. James Del Russo

Henderson, Nevada, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Skin Specialty Group

New York, New York, United States

Site Status

Derm Research Center of NY, Inc.

Stony Brook, New York, United States

Site Status

Zoe Draelos

High Point, North Carolina, United States

Site Status

OU Health Sciences Center - Dept. of Dermatology

Oklahoma City, Oklahoma, United States

Site Status

Allergy, Asthma and Dermatology Research Center, LLC

Lake Oswego, Oregon, United States

Site Status

Radiant Research

Anderson, South Carolina, United States

Site Status

Dermatology Associates of Knoxville

Knoxville, Tennessee, United States

Site Status

Arlington Center for Dermatology

Arlington, Texas, United States

Site Status

UTSW Medical Center at Dallas

Dallas, Texas, United States

Site Status

University of Texas Medical Branch at Galveston

Galveston, Texas, United States

Site Status

Tanner Clinic

Layton, Utah, United States

Site Status

Fletcher Allen Health Care

Burlington, Vermont, United States

Site Status

The Dermatology Centre

Calgary, Alberta, Canada

Site Status

Stratica Medical

Edmonton, Alberta, Canada

Site Status

Guildford Dermatology Specialists

Surrey, British Columbia, Canada

Site Status

Derm Research @ 888 Inc.

Vancouver, British Columbia, Canada

Site Status

Winnipeg Clinic

Winnipeg, Manitoba, Canada

Site Status

Dermadvances Research

Winnipeg, Manitoba, Canada

Site Status

Nexus clinical research

St. John's, Newfoundland and Labrador, Canada

Site Status

NewLab Clinical Research

St. John's, Newfoundland and Labrador, Canada

Site Status

Ultranova Skin care

Barrie, Ontario, Canada

Site Status

Lynderm Research inc.

Markham, Ontario, Canada

Site Status

North Bay Dermatology Centre

North Bay, Ontario, Canada

Site Status

XLR8 Medical Research Inc.

Windsor, Ontario, Canada

Site Status

Innovaderm Research Laval Inc.

Laval, Quebec, Canada

Site Status

Innovaderm Research Inc

Montreal, Quebec, Canada

Site Status

Siena Medical Research

Montreal, Quebec, Canada

Site Status

Licca Clinical Research Institute

Augsburg, , Germany

Site Status

Henrik Pres

Berlin, , Germany

Site Status

Meike Schroeder

Berlin, , Germany

Site Status

Beatrice Gerlach

Dresden, , Germany

Site Status

Kloverkorn, Windfried

Gilching, , Germany

Site Status

Otto-Von-Guericke-Universitat Magdeburg

Magdeburg, , Germany

Site Status

Michael Sebastian

Mahlow, , Germany

Site Status

Thomas Dirschka

Wuppertal, , Germany

Site Status

Outpatient Dermatology Department DUH

Budapest, , Hungary

Site Status

Margit Simola

Budapest, , Hungary

Site Status

Outpatient Dermatilogy Department XIX District

Budapest, , Hungary

Site Status

Waldemar Placek

Bydgoszcz, , Poland

Site Status

DERMED Specjalistyczne Gabinety Lekarskie

Lodz, , Poland

Site Status

Wojceiech Silny

Poznan, , Poland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Germany Hungary Poland

References

Explore related publications, articles, or registry entries linked to this study.

Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol. 2003 Sep;49(3 Suppl):S200-10. doi: 10.1067/s0190-9622(03)01154-x.

Reference Type BACKGROUND
PMID: 12963896 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RD.06.SPR.18088

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.